Clinical Research Directory
Browse clinical research sites, groups, and studies.
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
Sponsor: Qinghai Red Cross Hospital
Summary
This study aims to assess the impact of adding olanzapine to nutritional advice and standard anti-tumor therapy on the survival and safety of patients with locally advanced, unresectable or metastatic gastric cancer, esophageal cancer, hepato-pancreaticobiliary cancer, and lung cancer. Researchers seek to determine whether olanzapine can improve progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in advanced cancer patients who received standard anti-tumor therapy, and investigate the relationship between olanzapine-induced weight changes and patient survival.
Official title: Survival With the Addition of Olanzapine to Anticancer Therapy in Patients With Locally Advanced, Unresectable or Metastatic Gastric, Esophageal, Hepatopancreaticobiliary and Lung Cancer: a Randomized Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
230
Start Date
2024-03-20
Completion Date
2028-03-20
Last Updated
2024-03-29
Healthy Volunteers
Yes
Interventions
Olanzapine 2.5 MG
Oral olanzapine 2.5 mg once daily at bedtime until disease progression
Standard anti-tumor treatment
Clinicians choose the appropriate standard antitumor drug therapy based on the patient's specific situation
Nutritional advice
All patients enrolled in the study were required to undergo a nutritional assessment and were provided with nutritional advice based on their condition
Locations (1)
Qinghai Red Cross Hospital
Xining, Qinghai, China